Advice
In the absence of a submission from the holder of the marketing authorisation.
cinacalcet (Mimpara) is not recommended for use within NHS Scotland for the reduction of hypercalcaemia in patients with parathyroid carcinoma.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHS Scotland.
Download detailed advice29KB (PDF)
Medicine details
- Medicine name:
- cinacalcet (Mimpara)
- SMC ID:
- 271/06
- Indication:
- Reduction of hypercalcaemia in patients with parathyroid carcinoma
- Pharmaceutical company
- Amgen Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 08 May 2006